

| | |
|--------------------------|---|
| Product Name | : FGTI-2734 |
| Synonyms | : — |
| Cat No. | : M26215 |
| CAS Number | : 1247018-19-4 |
| Molecular Formula | : C ₂₆ H ₃₁ FN ₆ O ₂ S |
| Formula Weight | : 510.6 |
| Chemical Name | : — |
| Description | <p>FGTI-2734 can prevent membrane localization of KRAS, hence solving KRAS resistance problem and thwarting mutant KRAS patient-derived pancreatic tumors. FGTI-2734 is a RAS C-terminal mimetic dual farnesyl transferase (FT) and geranylgeranyl transferase-1 (GGT-1) inhibitor with IC₅₀s of 250 nM and 520 nM for FT and GGT-1, respectively. (In Vitro): FGTI-2734 (3-30 μM; 72 hours) inhibits both protein prenylation of HDJ2, RAP1A, KRAS and NRAS. FGTI-2734 inhibits KRAS membrane localization in RAS-transformed murine NIH3T3 cells and in mutant KRAS human cancer cells. FGTI-2734 (1-30 μM; 72 hours) induces CASPASE-3 and PARP cleavage in MiaPaCa2, L3.6pl and Calu6 cells. (In Vivo): FGTI-2734 (100 mg/kg/daily for 18 to 25 days; i.p.) only inhibited tumor growth in mutant KRAS-dependent tumors but not in mutant KRAS-independent tumors.</p> |
| Pathway | : Metabolic Enzyme/Protease |
| Target | : Transferase |
| Receptor | : NMDA receptor |
| Solubility | : — |
| SMILES | : <chem>Cn1cncc1CN(CCN(CCC1CCCCC1)S(=O)(=O)c1ccccc1)c1ccc(cc1F)C#N</chem> |
| Storage | : (-20°C) |
| Stability | : ≥ 2 years |
| Reference | : |

1. J. Lehmann, et al. CGS 19755, a selective and competitive N-methyl-D-aspartate-type excitatory amino acid receptor antagonist. J Pharmacol Exp Ther. 1988 Jul; 246(1):65-75.